Quite notably, the efficacy of combined therapies using lapatinib could be extended to other tissues colonized by metastatic breast cancer cells because dual HER2 blockade with trastuzumab and lapatinib inhibited tumor growth in patient-derived xenografts of HER2-amplified metastatic colorectal cancer [21]. The gene discussed is ERBB2; the disease is neoplasm.